<DOC>
	<DOCNO>NCT00400634</DOCNO>
	<brief_summary>The purpose double blind study determine whether CERE-120 ( adeno-associated virus serotype 2 [ AAV2 ] -neurturin [ NTN ] ) effective safe treatment patient idiopathic Parkinson 's Disease . CERE-120 administer via bilateral stereotactic injection target putaminal region brain . The design study involve approximately 34 patient receive CERE-120 treatment via stereotactic surgery approximately 17 patient receive sham stereotactic surgery ( CERE-120 administer ) .</brief_summary>
	<brief_title>Double-Blind , Multicenter , Sham Surgery Controlled Study CERE-120 Subjects With Idiopathic Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Diagnosis bilateral , idiopathic Parkinson 's Disease ( PD ) base UK Brain Bank criterion motor complication despite adequate oral antiparkinsonian therapy . At least 5 year disease duration , relative anticipate date surgery , since diagnosis PD . Males nonpregnant female 3575 year age , inclusive . A UPDRS motor scale score 30 great practically define condition 30day eligibility evaluation period . Stable dos antiparkinsonian medication parkinsonian feature 60day period precede surgical procedure . No condition would render subject unsuitable surgery , would interfere assessment efficacy safety trial . Subject 's informed consent prior performance studyspecific procedure . Subjects atypical secondary parkinsonism . Any subject , judgment investigator , participation study would pose safety risk include , limited , history clinically significant medical , psychiatric , laboratory abnormality . History treatment PD procedure involve intracranial surgery implantation device . MRI brain within 12 month surgical procedure indicate presence abnormality may interfere assessment safety efficacy would , judgment investigator , represent surgical risk subject . Any disorder precludes surgical procedure ( e.g. , sign sepsis inadequately treated infection ) alters wound heal . Receipt antiplatelet agent least 10 day prior surgical procedure . A score less equal 27 Folstein MiniMental examination perform eligibility evaluation period clinical evidence cognitive impairment would affect subject 's ability sign inform consent perform protocol require assessment . Chemotherapy , cytotoxic therapy , immunotherapy within 6 week prior surgical procedure . Vaccinations within 30 day prior surgical procedure . History , within 2 year surgical procedure , drug alcohol abuse . Treatment neuroleptic within 1 year surgical procedure . Any medical disability ( e.g. , severe degenerative arthritis , compromise nutritional state , peripheral neuropathy ) would interfere assessment efficacy safety trial would compromise ability subject undergo study procedure ( e.g. , MRI , PET ) , give inform consent . History prior gene transfer therapy . Treatment investigational agent within 60 day surgical procedure .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>